How does Streptozocin actually work inside my body to fight cancer?
Streptozocin is an alkylating drug that attaches to cancer cell DNA and breaks it apart, stopping the cells from dividing and forcing them to die [1][2]. It works best on slow-growing neuroendocrine and adrenocortical tumors, where it achieves 35–63% response rates in clinical trials.
In clinical trials, Streptozocin produces objective response rates of 35% in adrenocortical carcinoma and 63% in pancreatic neuroendocrine tumors when combined with 5-fluorouracil [1][4]. These numbers mean roughly one-third to two-thirds of patients see their tumors shrink by at least 50% on imaging. Median overall survival ranges from 14.8 to 18 months depending on cancer stage and whether other drugs are added.
Inside your cells, Streptozocin acts as an alkylating agent—it's like a chemical scissors that cuts DNA strands and prevents cancer cells from copying themselves [2]. Your body's repair machinery tries to fix the damage, but the breaks are too severe, so the cancer cell dies. Normal cells are also damaged, which is why side effects happen.
In real life, your oncologist gives you Streptozocin as a 500 mg/m² IV infusion once weekly for 6 weeks, then waits 4 weeks before repeating [1]. This schedule lets your bone marrow and kidneys recover between cycles. If your kidney function drops or nausea becomes unbearable, your doctor reduces the dose or switches to a gentler drug like gemcitabine.
Ask your oncologist: 'What's my tumor's growth rate, and why is Streptozocin better than gemcitabine for me?' This helps you understand if the kidney risk is worth the benefit for your specific cancer.